Our investigational monoclonal antibody, Xentuzumab – formerly known as get more info BI 836845 – represents a promising effort by Astellas Pharma targeting PD-1. This development initially focused on solid tumor applications, but latest

Milatuzumab, previously known as MEDI-115A, represents a groundbreaking treatment targeting human leukemia-lymphoma surface protein 1 (hLL1), also identifiable by the chemical 899796-83-9. This antibody exhibits high binding to hLL1, a protein frequently upregulated in multiple hematologic malign

The introduction of troglitazone, a potent glucose-lowering agent, marked a notable chapter in the management of type 2 diabetes. However, its discontinuation from the market due to serious hepatotoxicity spurred considerable investigation into related thiazolidinediones. Later pioglitazone and r